Clinical trial Recruiting at 2 sites Interventional Ages 4 to 8

Linking phonological and morpho-syntactic patterns in children with language disorders

Official title: A Developmental Framework For Linking Phonological And Morpho-syntactic Sequential Pattern Rules In Developmental Language Disorder: Production

Run by Father Flanagan's Boys' Home · NCT04558541 · Data updated 2026-11-12

This study is testing how well children with language disorders, aged 4 to 8, can learn sounds and word patterns to help create better ways to support their language development.

Quick facts

Study typeInterventional
Ages4 Years to 8 Years
SexAll
Enrollment400 (estimated)
SponsorFather Flanagan's Boys' Home
Academic / other
Locations2 sites (Tucson, Arizona and 1 other locations)
StatusRecruiting
StartedAugust 7, 2022
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedOctober 27, 2025
Trial IDNCT04558541 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are children aged 4 to 8 years with developmental language disorder, speech sound disorder, or typically developing children who meet specific cognitive and hearing criteria.

Probably not a fit

Patients who may not benefit from this study include those with intellectual disabilities or autism, as they do not meet the eligibility criteria.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study aims to explore the connection between phonological and morphological deficits in children with developmental language disorder (DLD) by assessing their ability to learn sequential patterns. The research combines insights from linguistics and language acquisition to develop a framework for understanding how these deficits may be linked. Children aged 4 to 8 years, including those with DLD and speech sound disorders, will undergo a series of assessments to evaluate their sensitivity to phonological rules and semantic category cues. The goal is to create earlier assessments and more effective interventions for children with language impairments.

Why it matters

Potential benefit: If successful, this study could lead to improved assessment tools and interventions for children with developmental language disorders.

How similar studies have gone: While the approach of linking phonological and morphological learning is innovative, similar studies have shown promise in understanding language acquisition in children.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Because clinical precision is required, 4- to 8-year-olds will complete a large test battery.

* All children (TD, DLD, DLD + SSD, SSD) will score above 75 on the Nonverbal Scale of the Kaufman Assessment Battery for Children (KABC-II), which is above the Diagnostic and Statistical Manual cut-off for intellectual disability, even considering the standard error of measurement.
* Hearing will be within normal limits
* Oral structures will be within normal limits (Robbins \& Klee, 1987).
* The Childhood Autism Rating Scale (Schopler et al., 2010) and parent report, will be used to rule out autism.

Children with DLD will meet standard criteria.

* Children with DLD will score below the cutoff of 87 on the Structured Photographic Expressive Language Test-P2 (SPELT-P2; Dawson et al., 2005) that has demonstrated high diagnostic accuracy for DLD.
* Children with DLD will perform below 80% in their spontaneous production of finite verb morphemes.
* Performance on a nonword repetition task will also support DLD status. Scores below 70% for total phonemes correct across all nonword lengths are greater than 1 SD below the mean for typical children.
* Speech production skills will be measured via the Goldman-Fristoe Test of Articulation-3 (GFTA-3; Goldman \& Fristoe, 2015) and the inconsistency subtest of the Diagnostic Evaluation of Articulation and Phonology (DEAP, Dodd, et al., 2006). Many 4- to 6-year-old children with DLD are expected to perform below expected levels on the GFTA-3; for this study half of the children with DLD will show performance below expected levels and half above a standard score of 85. Children with SSD will show impaired performance on the GFTA-3, but typical performance on grammatically weighted language measures (SPELT-P2 and finite verb morphemes). The DEAP serves as a standardized measure of segmental inconsistency and will provide a post hoc analysis that may be related to sequence pattern variability.

Performance on the following measures will serve as covariates and will not be exclusionary for DLD or SSD:

* Peabody Picture Vocabulary Test, 4th ed (Dunn \& Dunn, 1997)
* Expressive Vocabulary Test, 2nd ed (Williams, 1997)
* Verbal and nonverbal memory span.
* Because of the emphasis on English phonological and morpho-syntactic patterns, all participants will be monolingual English learners or report dominant exposure to English from infancy. Exposure to other languages will be documented.

Exclusion Criteria for all participants:

* Hearing impairment
* Intellectual impairment
* Autism
* Significant motor impairment.

Typical participants will be excluded if they show:

-Histories of developmental, speech, language, or hearing disorders.

Where it's running

  • University of Arizona
    Tucson, Arizona, United States
    Recruiting
  • Boys Town National Research Hospital
    Omaha, Nebraska, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.